LOOKING BEYOND 340B REFORM: MARKET SIGNALS SHAPE ONCOLOGY ACCESS
Rapid policy shifts from ASCO and CMS have thrust the 340B program into the spotlight, signaling a fundamental debate over who should benefit from drug savings and where cancer care will be delivered. As reimbursement pressures mount and stakeholders push back, health systems, payers, and providers must quickly adapt to a changing market that will reshape access, site-of-care decisions, and commercial strategy.
WHAT ASCO 2026 MEANS FOR MARKET ACCESS
Breakthrough data at ASCO 2026 underscored a new reality in oncology: scientific innovation alone isn’t enough—early, strategic planning for market access is now critical to ensuring therapies reach patients. As treatments grow more complex, success will depend on how well manufacturers address biomarker readiness, real-world adherence, and payer expectations from the outset.

